Recross Cardio Announces First Patient Enrolled in PROTEA-PFO US-Early Feasibility Study

Barchart · 3d ago

Novel membrane-based PFO Sealing system designed to address limitations of current stroke prevention devices

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Recross Cardio Inc., a structural heart company pioneering next-generation membrane sealing technology, today announces the first clinical implantation with its novel PFO Sealing system in the PROTEA-PFO Early Feasibility Study (EFS). The procedure was successfully performed by Dr. Carey Kimmelstiel and his interventional team at Tufts Medical Center in Boston, Massachusetts.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.